Search for a trial

A First-in-Human, Double-Blind, Randomised, Vehicle-Controlled Phase I/II Proof of Concept Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BEN2293 in Patients with Mild to Moderate Atopic Dermatitis.

PrimaryThe primary objective of this study is to assess the safety and tolerability of BEN2293, administered as multiple topical doses to increasing body surface area (BSA), in patients with mild to moderate AD.SecondaryPharmacokinetics· To…

A Phase 1, first-in-human, three-part, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAR443726 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.

PrimaryPart 3 - Repeated doses in atopic dermatitis (AD) patients - PDY16891* To evaluate the safety and tolerability of SAR443726 after repeated SC doses in adult participants with moderate-to-severe ADSecondaryPart 3 - Repeated doses in AD…

Phase I, Randomized, double-blind, vehicle-controlled study to evaluate the safety, tolerability, PK and efficacy of M528101 in Healthy Volunteers and AD subjects

This Phase 1, First in Human study is designed to assess the safety and systemic exposure (pharmacokinetics (PK)) of single dose (Part A,B) and multiple dose (thrice daily) for 14 days (Part C) topical M528101 Liquid 0.3% in healthy volunteers (Part…

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

Primary objective: The primary objective is to assess the efficacy and safety of nemolizumab (CD14152) after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

This study has been transitioned to CTIS with ID 2022-502936-38-00 check the CTIS register for the current data. The objective of the study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult subjects with…

A randomized, double blind, placebo controlled multicenter dose ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe Atopic Dermatitis

In this study we want to evaluate the safety and efficacy of the new drug ZPL389. ZPL389 is tested in various strengths in patients with moderate or severe atopic dermatitis. The effects of ZPL389 are compared with those of a placebo.

A phase 2, randomized, double blind, vehicle controlled, parallel group study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT), comprised of digoxin and furosemide in actinic keratosis

Primary Objective* To explore the pharmacodynamics of ICVT comprised of digoxin and furosemide (dual agent), digoxin (single agent), furosemide (single agent) in patients with AK. * To evaluate clinical efficacy of ICVT comprised of digoxin and…

A randomized, double-blind, placebo controlled, single center study to assess the efficacy and pharmacodynamics of Gladskin eczema cream BID in patients with mild to moderate atopic dermatitis.

Primary ObjectiveTo assess the efficacy of Gladskin Eczema Cream BID in patients with mild to moderate AD as assessed by EASI ScoreSecondary Objectives* To assess the pharmacodynamic effects of Gladskin Eczema Cream on the skin-microbiome, with…

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF
REGN3500 MONOTHERAPY AND COMBINATION OF REGN3500 PLUS
DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE
ATOPIC DERMATITIS

The primary objective of the study is to evaluate the efficacy of REGN3500monotherapy compared with placebo treatment in adult patients withmoderate-to-severe atopic dermatitis (AD).The secondary objectives of the study are:* To evaluate the…

An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study]

To compare the efficacy of Diacerein 1% Ointment to Control Ointment when applied once-daily in subjects with EBS.To compare the effects of Diacerein 1% Ointment to Control Ointment in subjects with EBS in:* Safety and tolerability* Pruritus * Pain…

A randomized, placebo-controlled, double-blind phase I study to explore safety, tolerability and pharmacodynamics of Cypep-1 in subjects with cutaneous warts

* To evaluate the safety and tolerability of CyPep-1 when applied on healthy skin for up to one week. * To evaluate the safety and tolerability of CyPep-1 when applied to cutaneous warts for up to four weeks.* To evaluate the activity of the CyPep-1…

A Randomized, Double-Blind, Vehicle-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Topically Applied INM-755 Cream on Epidermal Wounds in Healthy Volunteers

Primary Objective• To evaluate the local safety and tolerability of INM-755 cream following repeated once-daily topical applications for 14 consecutive days on wounded skin of healthy volunteers. Secondary Objectives• To evaluate the systemic safety…

A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to severe atopic dermatitis with the option of rescue treatment in flaring subjects.

Primary Objective- To evaluate and compare the maintenance of effect of two doses of PF-04965842 (200 mg and 100 mg once daily [QD]) and placebo in subjects aged 12 and above with moderate to severe atopic dermatitis who respond to an initial open-…

Trial NL77181.056.21

Publication withdrawn by sponsor

Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)

This study has been transitioned to CTIS with ID 2023-503435-17-00 check the CTIS register for the current data. Estimate the efficacy of apremilast compared with placebo in the treatment of Juvenile Psoriatic Arthritis (JPsA) in pediatric subjects…

A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and
Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients
With Moderate-To-Severe Atopic Dermatitis That Are Not Adequately Controlled With Cyclosporine or
For Whom Cyclosporine is Not Medically Advisable.

To evaluate the efficacy of lebrikizumab compared with placebo in patients not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients with Moderate-to-Severe Genital Psoriasis

Primary objective: To assess whether ixekizumab is superior to placebo at Week 12 in the treatment of patients with moderate-to-severe genital psoriasisMajor Secondary Objective:To assess whether ixekizumab is superior to placebo at Week 12 in the…

A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis

This study has been transitioned to CTIS with ID 2023-504869-23-00 check the CTIS register for the current data. 1. Sub-Study 1 (SS1): The primary study objective for SS1 is to evaluate the efficacy and safety of dose escalation to upadacitinib 30…

A Randomised, Double-Blind, Placebo-controlled, 32-week, Phase IIa trial to investigate the efficacy of OM-85 versus matched placebo in reducing disease severity in children aged 3 to 24 months with early clinical diagnosis of moderate atopic dermatitis

Primary Objective Primary objective is to assess the efficacy of OM-85 versus matched placebo in children with moderate AD in reducing disease severity over the first 16 weeks and the first 24 weeks of the treatment period.Secondary Objectives…

A placebo-controlled, double-blind randomized trial evaluating the effect of etidronate in young patients with pseudoxanthoma elasticum on ectopic mineralization.

This study has been transitioned to CTIS with ID 2024-512133-33-00 check the CTIS register for the current data. Primary Objective To determine if 24 months of treatment with etidronate halts the progression of arterial calcification in the legs and…